CIRM Funded Clinical Trials
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1
Disease Area:
Bone or Cartilage Disease, Hearing Loss, Intellectual Disability, Metabolic Disorders, Vision Loss
Trial Sponsor:
Immusoft Corporation
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A
